LYTIR

Insider · SEC Form 4 · Chief Development Officer

Yeleswaram Krishnaswamy

In the 12 months to Nov 8, 2026, on the open market: sold $2.6M of RAPP. Filed a median of 1 business day after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

  1. RAPPSold: Rapport Therapeutics, Inc. Aug 25, 2026 37,000 shares filed Aug 26, 2026 2 transactions 10b5-1 plan filing $1.9M
  2. RAPPSold: Rapport Therapeutics, Inc. Aug 24, 2026 13,160 shares filed Aug 26, 2026 232,862 shares held directly after, as filed 10b5-1 plan filing $658K
  3. RAPPSold: Rapport Therapeutics, Inc. Aug 19, 2026 404 shares filed Aug 20, 2026 246,022 shares held directly after, as filed 10b5-1 plan filing $20K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.